Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verano HoldingsNEOE:VRNO 75 Receivables Turnover is 6.58 as of Mar. 2026. GuruFocus rates NEOE:VRNO with a GF Score™ of 75/100 and a GF Value™ of C$11.28 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 950 Drug Manufacturers companies, Verano Holdings ranks better than 96.53% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Verano Holdings's Revenue for the
three
months ended in Mar. 2026 was C$286 Mil. Verano Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was C$43 Mil.
Hence, Verano Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 6.58.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Verano Holdings Receivables Turnover Related Terms
Verano Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Verano Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Verano Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verano Holdings Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Verano Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Verano Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verano Holdings (NEOE:VRNO) has a Receivables Turnover of 6.58 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Verano Holdings and its competitors. According to the industry distribution chart, Verano Holdings ranks #33 out of 950 companies in the Drug Manufacturers industry, placing it in the top 3.5%.
Is Verano Holdings' Receivables Turnover too high?
Verano Holdings' current Receivables Turnover is 6.58. The Drug Manufacturers industry median Receivables Turnover is 5.07. Verano Holdings' value of 6.58 is 29.8% above this industry median. Based on the distribution chart, Verano Holdings ranks #33 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Verano Holdings has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verano Holdings' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Verano Holdings ranks #33 out of 950 companies for Receivables Turnover. This places Verano Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Verano Holdings' value of 6.58 is 29.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verano Holdings's current Receivables Turnover of 6.58 is 29.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Verano Holdings and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verano Holdings's current Receivables Turnover is 6.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Verano Holdings (NEOE:VRNO) is currently considered Possible Value Trap. The stock's GF Value™ is C$11.28, compared to a current price of C$7.89 — trading 30.1% below its estimated fair value. The current Receivables Turnover is 6.58 and 29.8% above the Drug Manufacturers industry median of 5.07. Verano Holdings' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Verano Holdings (NEOE:VRNO), the current Receivables Turnover is 6.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verano Holdings (NEOE:VRNO) Overvalued in 2026?
Based on GuruFocus' analysis, Verano Holdings stock appears to be undervalued.
The current stock price of C$7.89 is trading 30.1% below its estimated GF Value™ of C$11.28.
GuruFocus considers Verano Holdings to be Possible Value Trap.
Key valuation signals for NEOE:VRNO:
Receivables Turnover: 6.58
GF Value™: C$11.28 vs. price of C$7.89 (30.1% below fair value)
Industry Position: 29.8% above the Drug Manufacturers median (#33 of 950)
No single metric tells the full story. See the NEOE:VRNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verano Holdings Corp is a vertically integrated, multi-state cannabis operator in the United States. The company operates through cultivation (wholesale) and retail segments. Its consumer brands include Encore, Avexia, MUV, Savvy, BITS, and Verano, while its retail dispensaries operate under brands such as Zen Leaf and MUV. The company derives the majority of its revenue from the retail segment.
75GF Score
Get the complete analysis for NEOE:VRNO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEOE:VRNO has been successfully added to your 
